LBA27 First-line systemic treatment in patients with initially unresectable colorectal cancer liver metastases (CRLM): Overall survival of the phase III CAIRO5 study of the Dutch Colorectal Cancer Group
Cornelis J.A. Punt(University of Amsterdam), R-J. Swijnenburg(Amsterdam University Medical Centers), Cornelis Verhoef(Erasmus MC Cancer Institute), Helgi H. Helgason(Medisch Centrum Haaglanden), Emile D. Kerver(OLVG), Mathijs P. Hendriks(Northwest Hospital), Mike S.L. Liem(Medisch Spectrum Twente), Jan Willem de Groot(Isala), Geert Kazemier(Amsterdam Neuroscience), Helga Droogendijk(Bravis Ziekenhuis), Joost M. Klaase(University Medical Center Groningen), Karen Bolhuis(The Netherlands Cancer Institute), Aysun Komurcu(Netherlands Comprehensive Cancer Organisation), Arjen M. Rijken(Amphia Ziekenhuis), Johannes H. W. de Wilt(Radboud University Nijmegen), M.J. van Amerongen(Sint Maartenskliniek), B. De Valk(Spaarne Ziekenhuis), Koert P. de Jong(University of Padua), O. J. L. Loosveld(Amphia Ziekenhuis), Marinde J. G. Bond(Utrecht University)
Cited by 10
Related Papers
Direct detection of early-stage cancers using circulating tumor DNA
|Science Translational Medicine|2017|1.1k
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2010|1k
From tumour heterogeneity to advances in precision treatment of colorectal cancer
|Nature Reviews Clinical Oncology|2016|692